Cancer biomarkers - An invitation to the table

被引:159
作者
Dalton, William S.
Friend, Stephen H. [1 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33613 USA
[2] Merck Res Labs, West Point, PA 19486 USA
关键词
D O I
10.1126/science.1125948
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.
引用
收藏
页码:1165 / 1168
页数:4
相关论文
共 23 条
[1]  
*AM CANC SOC, CANC STAT 2005
[2]  
[Anonymous], 2005, IMPLICATIONS GENOMIC
[3]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[4]   The external RNA controls consortium: a progress report [J].
Baker, SC ;
Bauer, SR ;
Beyer, RP ;
Brenton, JD ;
Bromley, B ;
Burrill, J ;
Causton, H ;
Conley, MP ;
Elespuru, R ;
Fero, M ;
Foy, C ;
Fuscoe, J ;
Gao, XL ;
Gerhold, DL ;
Gilles, P ;
Goodsaid, F ;
Guo, X ;
Hackett, J ;
Hockett, RD ;
Ikonomi, P ;
Irizarry, RA ;
Kawasaki, ES ;
Kaysser-Kranich, T ;
Kerr, K ;
Kiser, G ;
Koch, WH ;
Lee, KY ;
Liu, CM ;
Liu, ZL ;
Lucas, A ;
Manohar, CF ;
Miyada, G ;
Modrusan, Z ;
Parkes, H ;
Puri, RK ;
Reid, L ;
Ryder, TB ;
Salit, M ;
Samaha, RR ;
Scherf, U ;
Sendera, TJ ;
Setterquist, RA ;
Shi, LM ;
Shippy, R ;
Soriano, JV ;
Wagar, EA ;
Warrington, JA ;
Williams, M ;
Wilmer, F ;
Wilson, M .
NATURE METHODS, 2005, 2 (10) :731-734
[5]   Evaluating markers for the early detection of cancer: overview of study designs and methods [J].
Baker, SG ;
Kramer, BS ;
McIntosh, M ;
Patterson, BH ;
Shyr, Y ;
Skates, S .
CLINICAL TRIALS, 2006, 3 (01) :43-56
[6]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[7]   Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer [J].
Foekens, JA ;
Atkins, D ;
Zhang, Y ;
Sweep, FCGJ ;
Harbeck, N ;
Paradiso, A ;
Cufer, T ;
Sieuwerts, AM ;
Talantov, D ;
Span, PN ;
Tjan-Heijnen, VCG ;
Zito, AF ;
Specht, K ;
Hoefler, H ;
Golouh, R ;
Schittulli, F ;
Schmitt, M ;
Beex, LVAM ;
Klijn, IGM ;
Wang, YX .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (11) :1665-1671
[8]   Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].
Golub, TR ;
Slonim, DK ;
Tamayo, P ;
Huard, C ;
Gaasenbeek, M ;
Mesirov, JP ;
Coller, H ;
Loh, ML ;
Downing, JR ;
Caligiuri, MA ;
Bloomfield, CD ;
Lander, ES .
SCIENCE, 1999, 286 (5439) :531-537
[9]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[10]   From molecular to modular cell biology [J].
Hartwell, LH ;
Hopfield, JJ ;
Leibler, S ;
Murray, AW .
NATURE, 1999, 402 (6761) :C47-C52